Ocular Therapeutix Inc (OCUL)
5.70
-0.10
(-1.72%)
USD |
NASDAQ |
May 31, 16:00
5.69
-0.01
(-0.18%)
After-Hours: 20:00
Ocular Therapeutix Enterprise Value: 466.43M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 466.43M |
| May 30, 2024 | 481.92M |
| May 29, 2024 | 492.77M |
| May 28, 2024 | 502.06M |
| May 24, 2024 | 481.15M |
| May 23, 2024 | 481.92M |
| May 22, 2024 | 512.90M |
| May 21, 2024 | 528.39M |
| May 20, 2024 | 557.82M |
| May 17, 2024 | 539.23M |
| May 16, 2024 | 554.72M |
| May 15, 2024 | 557.82M |
| May 14, 2024 | 520.65M |
| May 13, 2024 | 457.14M |
| May 10, 2024 | 460.24M |
| May 09, 2024 | 488.12M |
| May 08, 2024 | 474.18M |
| May 07, 2024 | 502.06M |
| May 06, 2024 | 481.92M |
| May 03, 2024 | 539.23M |
| May 02, 2024 | 491.81M |
| May 01, 2024 | 360.29M |
| April 30, 2024 | 316.97M |
| April 29, 2024 | 326.25M |
| April 26, 2024 | 317.74M |
| Date | Value |
|---|---|
| April 25, 2024 | 233.42M |
| April 24, 2024 | 302.27M |
| April 23, 2024 | 357.20M |
| April 22, 2024 | 368.80M |
| April 19, 2024 | 391.24M |
| April 18, 2024 | 490.13M |
| April 17, 2024 | 756.23M |
| April 16, 2024 | 788.71M |
| April 15, 2024 | 790.26M |
| April 12, 2024 | 819.65M |
| April 11, 2024 | 864.52M |
| April 10, 2024 | 807.28M |
| April 09, 2024 | 847.50M |
| April 08, 2024 | 819.65M |
| April 05, 2024 | 889.27M |
| April 04, 2024 | 893.91M |
| April 03, 2024 | 890.82M |
| April 02, 2024 | 895.46M |
| April 01, 2024 | 927.95M |
| March 31, 2024 | 991.38M |
| March 28, 2024 | 1.232B |
| March 27, 2024 | 1.263B |
| March 26, 2024 | 1.246B |
| March 25, 2024 | 1.278B |
| March 22, 2024 | 1.290B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
91.12M
Minimum
Jun 06 2019
1.663B
Maximum
Dec 22 2020
472.72M
Average
351.65M
Median
Enterprise Value Benchmarks
| Amgen Inc | 218.38B |
| Assertio Holdings Inc | 52.20M |
| CytomX Therapeutics Inc | -17.82M |
| EyePoint Pharmaceuticals Inc | 258.48M |
| Cormedix Inc | 231.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.85M |
| Revenue (Quarterly) | 14.77M |
| Total Expenses (Quarterly) | 46.39M |
| EPS Diluted (Quarterly) | -0.49 |
| Gross Profit Margin (Quarterly) | 91.02% |
| Profit Margin (Quarterly) | -438.9% |
| Earnings Yield | -23.68% |
| Normalized Earnings Yield | -22.59 |